{"id":"NCT01034137","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","officialTitle":"U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Rheumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2009-12-17","resultsPosted":"2016-07-11","lastUpdate":"2016-07-11"},"enrollment":317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"placebo MTX","otherNames":[]},{"type":"DRUG","name":"placebo TCZ","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"Tocilizumab + Methotrexate","type":"EXPERIMENTAL"},{"label":"Tocilizumab + Placebo Methotrexate","type":"ACTIVE_COMPARATOR"},{"label":"Methotrexate + Placebo Tocilizumab","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with early rheumatoid arthritis. Patients will be randomized to receive either tocilizumab (8mg/kg iv every 4 weeks) plus weekly methotrexate (po in ascending doses), or tocilizumab (8mg/kg iv every 4 weeks) plus placebo, or methotrexate plus placebo. Anticipated time on study treatment is 2 years, and target sample size is 300.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Remission Rate At Week 104","timeFrame":"Week 104","effectByArm":[{"arm":"Tocilizumab + Methotrexate","deltaMin":85.8,"sd":null},{"arm":"Tocilizumab + Placebo Methotrexate","deltaMin":83.5,"sd":null},{"arm":"Methotrexate + Placebo Tocilizumab","deltaMin":44.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"< 0.001"},{"comp":"OG001 vs OG002","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"0.616"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":21,"countries":["Netherlands"]},"refs":{"pmids":["32926395","30322408","29760159","29095992","29029185","28728565","27287832"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":106},"commonTop":["Nasopharyngitis","Nausea","Fatigue","Alanine aminotransferase increased","Headache"]}}